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1. CASE REPORT {#joa312022-sec-0001}
==============

A 60‐year‐old woman with hypertrophic obstructive cardiomyopathy (HOCM) underwent alcohol septal ablation (ASA) in 2004 and had implantable cardioverter defibrillator (ICD) (Generator; Protecta XT DR, Medtronic, Minneapolis, MN, USA) with atrial and ventricular leads (TENDRIL SDX, model‐1488T, St. Jude Medical, St. Paul, MN, USA, and ENDOTAK, ENDOTAKENDURANCE EZ, model‐0154, Guidant, Indianapolis, IN, USA) for ventricular tachycardia in 2005 (Figure [1](#joa312022-fig-0001){ref-type="fig"}A). The maximal pressure gradient of the left ventricular outflow tract decreased from 181 to 7 mm Hg after the ASA. Although she had better hemodynamics with unchanged tricuspid regurgitation (TR) (mild), her paroxysmal atrial fibrillation (AF) had occurred more frequently few years after the procedure. In 2010, transthoracic echocardiography (TTE) demonstrated moderate TR with evidence of annular dilation; tricuspid annular diameter in 4‐chamber view increased from 35 to 40 mm. In 2011, device interrogation revealed the absence of atrial P‐wave amplitude. In 2014, transesophageal echocardiography (TEE) revealed that the ICD lead limited septal leaflet motion (Figure [1](#joa312022-fig-0001){ref-type="fig"}B). On her last hospitalization in 2015, the chest X‐ray revealed the bilateral pleural effusion and cardiomegaly, and TTE demonstrated severe TR (Figure [1](#joa312022-fig-0001){ref-type="fig"}C, D). Despite maximal medical treatment, she died due to severe heart failure on the 24th day after admission.

![A, Atrial and ventricular lead placement with adequate slack (\*) at the time of procedure. B, Transesophageal echocardiography showing ventricular lead limits septal leaflet motion (\*). C, D, Chest X‐ray and echocardiographic finding on her third hospitalization. Arrow indicates significant tricuspid regurgitation](JOA3-34-90-g001){#joa312022-fig-0001}

Autopsy findings revealed that the ICD lead was entrapped by the right ventricular (RV) fibrous tissue considered part of papillary muscle anomaly attached to the contralateral side of the RV wall (Figure [2](#joa312022-fig-0002){ref-type="fig"}A). In addition, in the right atrium (RA), the connective tissue tunnel covered the atrial and ventricular leads. The tip of the atrial lead lost contact to the atrial wall, although there was the fibrous string between the tip of the atrial lead and the wall (Figure [2](#joa312022-fig-0002){ref-type="fig"}B).

![A, Autopsy findings showing the ventricular lead is entrapped by fibrous tissue (arrow) and located just next to septal leaflet. Asterisk shows the anomaly papillary muscle in right ventricle. B, Tip of the atrial lead lost contact to the atrial wall (\*). Arrow indicates connective tissue tunnel covering the atrial and ventricular leads](JOA3-34-90-g002){#joa312022-fig-0002}

2. DISCUSSION {#joa312022-sec-0002}
=============

Although AF is well known as an independent predictor of poor outcomes in HOCM, this is the first report, which demonstrated how AF negatively affected in right‐side heart in HOCM with ICD.[1](#joa312022-bib-0001){ref-type="ref"} The pathological finding demonstrated the papillary muscle anomaly. In the right ventricle, the papillary muscle and chordae can vary individually even in the normal heart.[2](#joa312022-bib-0002){ref-type="ref"} In addition to the previous study showing the abnormal structure in HOCM can possibly cause RV outflow obstruction, variation of RV anatomy is clinically important in HOCM, because it is not uncommon for having the ICD for prevention of sudden death in this population.[2](#joa312022-bib-0002){ref-type="ref"}

Another pathological finding demonstrated that the lead entrapment in papillary muscle and the connective tissue tunnel covered the atrial and ventricular leads in the RA. TR is rarely significant immediately after device‐lead implantation, probably because the fibrous tissue formation due to the inflammatory change, which potentially limits its flexibility, starts at least weeks to months later.[3](#joa312022-bib-0003){ref-type="ref"}, [4](#joa312022-bib-0004){ref-type="ref"}, [5](#joa312022-bib-0005){ref-type="ref"} In this patient, restriction of septal leaflet likely due to lead contact was evident by TEE late after ICD implantation. More frequent AF might dilate RA, which restricted septal leaflet more significantly by RV lead retraction. Although lead entrapment contributes to subsequent deterioration of TR, AF became more frequent after ICD implantation and also caused exacerbation of TR due to annular dilation, suggesting more aggressive treatment to AF might prevent or minimize her refractory heart failure.[1](#joa312022-bib-0001){ref-type="ref"}, [5](#joa312022-bib-0005){ref-type="ref"} Subcutaneous ICD for avoiding passing through tricuspid valve may also be helpful in such patient.

The fibrous tissue between the tip of the ICD lead and the RA wall is consistent with further expansion of the RA and dilation of the tricuspid annulus after its implantation. On the other hand, the RV was not further dilated, which is consistent with unchanged pulmonary artery pressure, main contributor of tricuspid tethering.[2](#joa312022-bib-0002){ref-type="ref"}
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